Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

NCT01454934 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01454934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01454934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 9, 2011
Completion date
May 2, 2016
Enrollment
540 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)